Cargando…
Emerging therapies and challenges in spinal muscular atrophy
Spinal muscular atrophy (SMA) is a hereditary neurodegenerative disease with severity ranging from progressive infantile paralysis and premature death (type I) to limited motor neuron loss and normal life expectancy (type IV). Without disease‐modifying therapies, the impact is profound for patients...
Autores principales: | Farrar, Michelle A., Park, Susanna B., Vucic, Steve, Carey, Kate A., Turner, Bradley J., Gillingwater, Thomas H., Swoboda, Kathryn J., Kiernan, Matthew C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396275/ https://www.ncbi.nlm.nih.gov/pubmed/28026041 http://dx.doi.org/10.1002/ana.24864 |
Ejemplares similares
-
Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy
por: Farrar, Michelle A., et al.
Publicado: (2011) -
Inherited Paediatric Motor Neuron Disorders: Beyond Spinal Muscular Atrophy
por: Teoh, Hooi Ling, et al.
Publicado: (2017) -
Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives
por: Farrar, Michelle A, et al.
Publicado: (2018) -
Revisiting the role of mitochondria in spinal muscular atrophy
por: James, Rachel, et al.
Publicado: (2021) -
Therapeutic strategies for spinal muscular atrophy: SMN and beyond
por: Bowerman, Melissa, et al.
Publicado: (2017)